First 10-YTear Follow-Up Shows That Treatment With AVONEX Leads To Long-Term Benefits In Early Multiple Sclerosis Patients

Links shared publicly online about this topic.

  • 2,074
    total visits

First 10-YTear Follow-Up Shows That Treatment With AVONEX Leads To Long-Term Benefits In Early Multiple Sclerosis Patients

medicalnewstoday.com

Biogen Idec (NASDAQ: BIIB) has announced data results from the CHAMPIONS (Controlled High-Risk AVONEX® (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surve

View full resource at medicalnewstoday.com

Tags: Neurology, Multiple Sclerosis, Multiple Sclerosis Medication, Avonex, Rebif, Biogen Idec

  • Share

Most Recently Shared on May 2, 2009 at 11:07 am By:

LisaEmrich Lisa Emrich

MedNewsToday: First 10-YTear Follow-Up Shows That Treatment With AVONEX Leads To Long-Term Benefits.. http://tinyurl.com/cfwmlh

3 years ago...

First Ten-Year Follow-Up Shows That Treatment With AVONEX® Leads To Long-Term Benefits In Early Multiple Sclerosis Patients

medicalnewstoday.com — “Biogen Idec (NASDAQ: BIIB) today announced data results from the CHAMPIONS (Controlled High-Risk AVONEX® (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic SurView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on September 8, 2009 at 11:52 am By:

LisaEmrich Lisa Emrich Patient Expert

MedNewsToday: First Ten-Year Follow-Up Shows That Treatment With AVONEX® Leads To Long-Term Benefit.. http://bit.ly/1qsCyy

3 years ago...

First Ten-Year Follow-Up Shows That Treatment With AVONEX® Leads To Long-Term Benefits In Early Multiple Sclerosis Patients

medicalnewstoday.com — “Biogen Idec (NASDAQ: BIIB) announced data results from the CHAMPIONS (Controlled High-Risk AVONEX® (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic SurveillaView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on July 4, 2009 at 11:05 am By:

LisaEmrich Lisa Emrich Patient Expert

MedNewsToday: First Ten-Year Follow-Up Shows That Treatment With AVONEX® Leads To Long-Term Benefit.. http://tinyurl.com/nguutu

3 years ago...

First Ten-Year Follow-Up Shows That Treatment With AVONEX Leads To Long-Term Benefits In Early Multiple Sclerosis Patients

medicalnewstoday.com — “Biogen Idec (NASDAQ: BIIB) announced data results from the CHAMPIONS ( C ontrolled H igh-Risk A VONEX ® (interferon beta-1a) M ultiple Sclerosis (MS) P revention Study I n O ngoing N eurologiView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on May 4, 2009 at 3:03 pm By:

LisaEmrich Lisa Emrich Patient Expert

MedNewsToday: First Ten-Year Follow-Up Shows That Treatment With AVONEX Leads To Long-Term Benefits.. http://tinyurl.com/cpbwxv

3 years ago...

Advertisement